Dr Reddy's Drops Obeda: A Smooth Move in Diabetes Game

Yo, peep this! Dr Reddy's just rolled out their new diabetes player, Obeda, in India, right after semaglutide lost its patent. Costing ₹4,200 a month, it’s a steal compared to Ozempic. With plans to drop 12 million pens this year, they’re aiming for the top five in the GLP-1 game, fo' shizzle!